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MicrovesiclesBody ﬂuids contain surprising numbers of cell-derived vesicles which are now thought to contribute to both
physiology and pathology. Tools to improve the detection of vesicles are being developed and clinical applica-
tions using vesicles for diagnosis, prognosis, and therapy are under investigation. The increased understanding
why cells release vesicles, how vesicles play a role in intercellular communication, and how vesiclesmay concur-
rently contribute to cellular homeostasis and host defense, reveals a very complex and sophisticated contribution
of vesicles to health and disease.
© 2012 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
The release of vesicles by cells is a common and evolutionary con-
served process, because both prokaryotes1,2 and eukaryotic cells3,4
release such vesicles into their environment. The underlying molecu-
lar mechanisms of formation, cargo sorting, and release of vesicles are
still largely unexplored.5–7 It is appealing to consider why cells re-
lease vesicles. In complex multicellular organisms or within (mixed)
populations of bacteria, vesicles offer an elegant solution to exchange
biomolecules such as proteins, second messengers, and genetic infor-
mation3,4 or to get rid of redundant and/or dangerous intracellular or
membrane-associated compounds.8,9 Once the biomolecules have
been packaged within vesicles they will be less susceptible to degra-
dation. Packaging also offers the opportunity to store cargo in a highly
efﬁcient manner, and vesicles can be equipped with cell type-speciﬁc
adhesion receptors so that the cargo will be delivered only at dedicat-
ed target cells. In the case of clearance of vesicles, concentrating
harmful or redundant components into vesicles, such as chemothera-
peutic drugs or (parts of) microorganisms, reduces the risk of “envi-
ronmental contamination”10,11 and at the same time facilitates
cellular survival and may protect the host, e.g. by supporting defense
processes such as coagulation and inﬂammation.3,4,12
Phospholipid bilayer-enclosed vesicles from eukaryotic cells will
be collectively called extracellular vesicles (EVs) in this review
when appropriate. Recent review reports that at least four different
types of EVs have been deﬁned based on phenotype and physicalistry (RoomB1-234), Academic
reef 9, 1105AZ Amsterdam, The
2.
and).
vier OA license.characteristics.3 These types of vesicles are microvesicles (MVs),
exosomes, membrane particles and apoptotic vesicles, but it is
unclear whether each of these types indeed represents distinct
types of vesicles.3 Despite the lack of consensus on classiﬁcation of
EVs, three common types, MVs, exosomes, and apoptotic vesicles,
are distinguished unanimously. MVs and exosomes have attracted
much attention in the past years because the evidence is increasing,
althoughmainly from in vitro studies, that both types of vesicles can con-
tribute not only to intercellular communication, but also to processes
such as coagulation, angiogenesis, cell survival, waste management,
modulation of the immune response, and inﬂammation.3,4
EVs are widely distributed, and they have been found in all human
body ﬂuids that have been investigated thus far in both physiological
and pathological conditions, including blood, urine, saliva, mother
milk, and cerebrospinal and synovial ﬂuid.3,4 The numbers, cellular
origin, composition and functional properties of EVs are associated
with the type of body ﬂuid, diseases and disease states such as
cancer,13–15 cardiovascular disease,16,17 and inﬂammation.18,19
Despite extensive research on EVs, there are severalmajor challenges
to be faced, including the proper detection of EVs. Most information on
diameter and size distribution of EVs comes from measurements by
transmission electron microscopy (TEM).20–22 As based on TEM mea-
surements, most EVs have a diameter less than 100 nm, which is too
small to be detected by standard cell-basedmethodologies. Towhich ex-
tent the diameter of single vesicles and the size distribution of a popula-
tion of vesicles as determined by TEM reﬂects the true size and size
distribution of vesicles in solution, however, are unknown, because
TEM measurements require sample ﬁxation and dehydration, i.e. pro-
cesses likely to affect the size and morphology of vesicles. Newmethod-
ologies such as atomic force microscopy (AFM), nanoparticle tracking
analysis (NTA) or resistive pulse sensing (RPS) are capable of detecting
32 Y. Yuana et al. / Blood Reviews 27 (2013) 31–39single vesicles directly in solution and no ﬁxation or dehydration is re-
quired. Thus, these methodologies are more likely to provide informa-
tion on the real diameter of vesicles. Importantly, development of
commonly accepted and acceptable referencematerials will be essential,
not only to deﬁne the original diameter and size distribution of EVs, but
also to be able to compare results between laboratories.
In this review, we will present an overview on the presence and
biological relevance of EVs in human body ﬂuids in normal and path-
ological conditions, and we will provide an overview on their poten-
tial clinical applications, including their use as biomarkers and novel
therapeutic agents.
2. Terminology of EVs
As mentioned before, there is no consensus regarding the classiﬁca-
tion and terminology of different types of EVs.3 Recent evidence sug-
gests that different types of EVs have more similarities than thought
previously.4,21 For example, the membranes of EVs are relatively
enriched in detergent-resistant membrane domains, also known as
lipid rafts, compared to plasma membranes23–26 and there is much
overlap in the density and diameter of EVs.3,4 In fact, even for a single
type of vesicle conﬂicting size ranges have been reported, and there is
no consensus on this matter as illustrated in Table 1. The size of
exosomes is below 100 nm in most references, but the size of the
MVs (also called microparticles) varies widely between investigators.
Furthermore, supposedly different types of EVs may share common
membrane proteins. For example, P-Selectin (CD62p),which is exposed
on activated platelets and platelet derived-MVs (PMVs), is also exposed
on platelet-derived exosomes.20 In addition, it cannot be excluded that
many unique characteristics that have been ascribed to an isolated and
puriﬁed population of vesicles, such as the presence of a particular
mRNAormiRNA inexosomes, are due to contaminationby larger vesicles,
vice versa. Thus, extreme care is necessarywhen terms for speciﬁc subsets
of vesicles are being used.
3. Formation and shedding of EVs
Cells release EVs upon activation and during apoptosis in vitro,
i.e. under conditions of cell stress.10,11,25,27–30 Under cell stress MVs
and exosomes are being formed (Fig. 1). The formation of MVs seems
to be initiated by an increase in the cytosolic concentrations of calcium
ions. The increase of calcium ions activates scramblase and calpain,
which leads to a loss of membrane phospholipid asymmetry (scramblase
action) and calcium dependent degradation of various proteins (calpain
action), which in some way allow the outward budding of MVs from
the plasma membrane.5,31 As a consequence, cells and MVs may expose
phosphatidylserine (PS). This is illustrated in a rare bleeding disorder,
Scott syndrome, in which a defective scramblase activity results in a re-
duced transport of PS to the platelet surface as well as the release of aTable 1
The size distribution of EVs.
Type of vesicles Size (nm) Detection References
Microvesicles
(microparticles)
20–50 TEM 138
100–1000 TEM 20
40–70 TEM 139
200–800 TEM 140
180 (mean) AFM 128
10–475 (mean 67.5) AFM 125
30–90 (mean 50) AFM with microﬂuidics 135
100–500 TEM 22
Exosomes 40–100 TEM 20
30–100 TEM 141
50–100 NTA 130
TEM (transmission electron microscopy), AFM (atomic force microscopy), FCM (ﬂow
cytometry), NTA (nanoparticle tracking analysis).reduced number of PS-exposing MVs.8,32 Although many studies have
shown that MVs may expose PS, also here there are still many questions
to be answered. Exposure of PS byMVs seems to depend on their cellular
origin, the underlying mechanism of formation, the presence of PS-
binding proteins such as lactadherin that may artifactually shield PS
from detection in our analyses, and, importantly, pre-analytical condi-
tions such as collection, handling and storage.27,28,33–35 Therefore, the de-
tection and characterization of MVs based on PS exposure need to be
reconsidered.
The biogenesis of exosomes begins with the inward budding of
small parts of the plasma membrane, containing several antigens ex-
posed on that outer membrane. These small intracellular vesicles
form the early endosome. Then, formation of intraluminal vesicles
(ILVs) by inward budding of the limiting membrane of endosome oc-
curs. Once the endosome contains ILVs, it is called a multivesicular
body (MVB; Fig. 1).6 ILVs have a cytosolic-side inward orientation
and thus expose the extracellular domains of transmembrane pro-
teins. Four different mechanisms may contribute to protein sorting
towards ILVs: (1) mono-ubiquitination and the endosomal sorting
complex required for transport (ESCRT) machinery that facilitates
the trafﬁcking of ubiquitinated proteins from endosomes to lyso-
somes via MVBs, (2) association of proteins with detergent-resistant
membrane domains or lipid rafts, (3) higher-ordered protein oligo-
merization, and (4) ceramide-dependent segregation into endosomal
microdomains.36–39 In fact, several proteins involved in the biogene-
sis of exosomes have been used to identify exosomes. Examples of
such proteins are ESCRT-associated proteins such as PDCD6IP (Alix)
and tumor susceptibility gene 101, tetraspanin molecules (CD9, CD63
and CD81) and heat shock protein 70.20,40–42 TheMVBs fusewith either
lysosomes for cargo degradation or with the plasma membrane to
secrete the ILVs as exosomes. The concentration of calcium ions within
the MVBs also plays a role in secretion of exosomes.43
Because vesicles which are indistinguishable from exosomes may
also be directly budded from the plasma membrane,3,6 and because
at least part of the MVB membranes may be deep invaginations of
the plasma membrane, it is unclear whether ILVs, exosomes, and
MVs are truly separate entities. So to summarize, to which extent
EVs contain truly distinct types of vesicles requires further investiga-
tion, and at present no tools are available to purify a single type or
population of vesicle based on size or density.3
EVs expose tissue/cell type-speciﬁc marker proteins of their parent
cell.3,4,44 When a sufﬁcient number of such marker proteins are ex-
posed, the cellular origin of a vesicle can be determined by e.g. ﬂow cy-
tometry using antibodies directed against such marker proteins. This is
illustrated in Table 2, inwhich a shortlist of commonly usedmarker pro-
teins is summarized for analysis of vesicles in human blood (CD: cluster
of differentiation).4. Sources of EVs in human body ﬂuids
The numbers, cellular origin, composition and functional proper-
ties of EVs are not only disease (state) dependent, but also depend
on the body ﬂuids being studied. The major populations of EVs in a
body ﬂuid usually reﬂect the cells that are present in that particular
body ﬂuid and that surround the body ﬂuid. Examples of the latter
are vesicles from synoviocytes which are present in joint (synovial)
ﬂuid, and vesicles from endothelial cells (ECs) in blood. We will brief-
ly summarize the cellular origin presence of EVs in blood, urine, sali-
va, cerebrospinal and synovial ﬂuids in the following paragraphs.
In peripheral blood of a healthy subject, platelets and erythrocytes
are themajor sources of EVs, but in certain disease states such as sepsis,
cardiovascular disease (CVD), or cancer, also MVs from monocytes,
granulocytes, lymphocytes, ECs, and cancer cells can be present.45 Pe-
ripheral blood also contains exosomes,46 although the cellular origin
of these vesicles is unknown.
Fig. 1. Formation and shedding of extracellular vesicles. Microvesicles (MVs, 1), also called microparticles, are formed directly from the cell membrane by a shedding process of
which the exact molecular mechanisms are largely unknown. Speciﬁc targeting of membrane proteins and lipids to the MV is known to occur. For the formation of exosomes, in-
vagination of small parts of the cell membrane, with speciﬁc membrane protein components incorporated, starts the formation process.6 The small vesicles are taken up by this
endocytosis process into early endosomes. The proteins are then packaged into intraluminal vesicles (ILVs) upon inward budding of the membrane of the endosome, transforming
the endosome into multivesicular bodies (MVBs). When proteins are destined for degradation, MVBs fuse with the lysosomal membrane and release ILVs into the lysosome for
degradation. Alternatively, MVBs fuse with the plasma membrane and ILVs are released into the extracellular space as exosomes (2). Exosomes (3) may also be formed directly
by outward budding of plasma membrane, thus resembling the formation of MVs.3 Please keep in mind that there is no consensus whether endosomes are intracellular organelles
or deep invaginations of the plasma membrane. When endosomes would be deep invaginations, the consequence is that ILVs would be extracellular and thus are indistinguishable
from exosomes. In fact, then the term “ILVs” would be redundant.
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numbers of exosomes or exosome-like vesicles.47 These exosomes
expose CD24 and aquaporin-2, therefore, are likely to originate
from kidney cells48 and from epithelial cells facing the renal tu-
bule lumen.49 Urine contains also larger vesicles, but thus far the
characterization of these two types of vesicles in urine has been
problematic.50
In saliva from healthy individuals, the larger vesicles, MVs, are de-
rived mainly from epithelial cells and granulocytes, whereas the
smaller vesicles, i.e. exosomes or vesicles resembling exosomes, are
mainly from epithelial cell origin.51
Cerebrospinal ﬂuid also contains EVs.52 In vitro, various types of
brain cells such as astrocytes, microglia, oligodendrocytes and neu-
rons release exosomes.53 The source of the EVs in cerebrospinal
ﬂuid, however, is presently unknown.
Synovial ﬂuid of rheumatoid arthritis (RA) patients and patients
with other types of arthritis contain MVs.18,54 Most of these MVs orig-
inate from cells associated with inﬂammation, such as monocytes and
granulocytes. In addition, synovial ﬂuid also contains vesicles from
synovial ﬁbroblasts.55 Taken together, every body ﬂuid has a clearly
distinct vesicle proﬁle.Table 2
Antibodies for staining microvesicles derived from different cell types.
Cellular origin Cell surface marker
Erythrocyte CD235a
Lymphocyte CD3, CD4 and CD8
Neutrophil/granulocyte CD66b, CD66e
Monocyte CD14
Platelet CD41, CD42, CD61
Endothelial cell CD105, CD144, CD62e5. Functions of EVs
In the following paragraphs, an overview will be presented of the
cellular functions, which are summarized in Fig. 2.
5.1. Angiogenesis
EVs have pro- as well as anti-angiogenic properties.30,56–62 Angio-
genesis involves the formation and growth of new blood vessels to
provide expanding tissues and organs with oxygen and nutrients,
and concurrently remove the metabolic waste.63
Cultured ECs release MVs containing metalloproteinase proteins
MMP-2 and MMP-9.64 These endothelial-MVs (EMVs) promote ma-
trix degradation, thereby promoting the formation of new blood ves-
sels. Also MVs from platelets (PMVs) promote proliferation, survival,
migration, and formation of capillary-like structures of ECs in vitro.59
PMVs also induce angiogenesis in vivo because subcutaneous injec-
tion of PMVs promotes the development of endothelial capillaries in
mice, and injection of PMVs in the ischemic heart muscle of rats in-
creases revascularization.60 Both processes are apparently mediated
by vascular endothelial growth factor (VEGF), which is secreted
upon platelet activation and seems to be associated with the PMVs.
This also holds true for other growth factors, such as basic ﬁbroblast
growth factor and platelet derived growth factor.60 However, because
isolated fractions of PMVs may still contain low levels of growth fac-
tors that have become released by platelets during blood collection
and handling, one has to be careful with the interpretation of these
results.
Induction of angiogenesis by PMVs or other vesicles may also
support tumor angiogenesis and metastasis. For example, binding
of PMVs tometastatic lung cancer cells triggers the expression of ma-
trix metalloproteinases (MMP-9, MMP-2 and MMP-14), VEGF,
Fig. 2. Functions of extracellular vesicles.
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cancer cells release exosomes which promote tumor angiogenesis.
Glioblastoma tumor cells release exosomes containing mRNA and
miRNA involved in remodeling the tumor stroma and enhancing
tumor growth.30 These glioma-derived exosomes are also enriched
in angiogenin, IL-6 and IL-8, all of which have been implicated in
glioma angiogenesis and increased malignancy.30
Besides pro-angiogenic features, EMVs also inhibit angiogenesis as
they can stimulate the production of endothelial reactive oxygen spe-
cies (ROS).66 Lymphocyte-derived MVs generated after actinomycin
D treatment in vitro decrease nitrite oxide (NO) and increase ROS
production by stimulating phosphatidylinositol 3-kinase, xanthine
oxidase and nicotinamide adenine dinucleotide phosphate oxidase
pathways.56,58 Thus, reduced NO and increased ROS productions in-
hibit angiogenesis.
5.2. Intercellular communication
EVs can transfer biomolecules to recipient cells e.g. adhesion re-
ceptors or ligands, cytokines, and genetic information, and therefore
are capable of changing the composition and function of recipient
cells. For example, PMVs can transfer the platelet ﬁbrinogen receptor
(integrin αIIbβ3) to cancer cells, thereby increasing the ability of the
cancer cells to adhere to ECs in vitro.65,67 One has to bear in mind,
however, that in vivo the situation may be far more complex because
such vesicles may also inhibit the interaction between cancer cells
and ECs.
Patients with stage 3 or 4 melanomas have increased levels of
phosphorylated MET, a receptor tyrosine kinase, in tumor exosomes,
and circulating bone marrow progenitor cells from these patients
also show an increased expression of phosphorylated MET compared
to cells from healthy volunteers.68 In a mouse melanoma model,
tumor-derived exosomes promote tumor cell proliferation by transfer
of MET to bone marrow cells.68 Thus, tumor-derived exosomes are
likely to transfer MET and educate bone marrow progenitor cells to
support tumor growth and metastasis in vivo.
Tumor exosomes transfer mutant epidermal growth factor recep-
tor (EGFRvIII) RNA into platelets. Nilsson et al.69 showed that plate-
lets, after incubation with vesicles from EGFRvIII-positive glioma
cells, contain EGFRvIII RNA. In addition, they showed that EGFRvIII
RNA was detectable in platelets from 80% of the EGFRvIII-positive gli-
oma patients, but absent in platelets from healthy individuals. The
presence of tumor-associated messages is apparently not unique for
platelets from glioma patients, because platelets from prostate cancer
patients—but not from healthy controls—contain RNA encoding the
prostate cancer marker PCA3. However, one must bear in mind that
platelets and vesicles overlap in size (diameter), and isolation and pu-
riﬁcation of either platelets without contaminating vesicles or vesi-
cles without contaminating platelets is and will likely remain a
tremendous challenge. This may lead to misinterpretation of results
on the exact origin of certain components. Moreover, isolated vesicles
also contain DNA, which further complicates analysis and interpreta-
tion of results.Transfer of receptors by EVs can also support intracellular signaling.
Human umbilical vein ECs produce exosomes that contain Delta-like 4
(Dll4), a notch ligand that is up-regulated during angiogenesis. D114
is transferred between ECs by exosomes in vitro and in vivo, suggesting
that such exosomes are indeed capable of transferring Delta like/Notch
signaling to recipient cells.70
5.3. Cell survival
After treatment with chemotherapeutic drugs, tumor cells release
vesicles which contain the corresponding drugs. Experiments with
cisplatin10 and doxorubicin11 on cultured resistance cancer cell lines
conﬁrm drug accumulation and expulsion in shed vesicles. Although
these studies show that the release of vesicles may support tumor
cell survival by removing the chemotherapeutic drug, the relative
contributions of exosomes to reduce the intracellular drug concentra-
tion, however, is thought to be modest.71 Alternatively, MVs can
transfer multidrug transporters, such as P-glycoprotein (P-gp), be-
tween cells. MVs released from drug-resistant cancer cells in vitro
transfer functional P-gp to drug-sensitive cells.72 To which extent
such mechanisms contribute to drug resistance in vivo, however, is
still unknown, and there may be other mechanisms via which vesicles
contribute to tumor progression. For example, MVs from humanmes-
enchymal stem cells (MSCs) enhance the survival of cisplatin-induced
acute kidney injury in a mouse model by about 80% by increasing the
expression of anti-apoptotic genes and down-regulating the expres-
sion of pro-apoptotic genes.73
5.4. Inﬂammation and Immune response
EVs can affect or enhance autoimmunity and inﬂammation. Synovial
ﬂuid of RA patients contains strongly coagulant and pro-inﬂammatory
vesicles which are mainly of leukocytic origin.54 Such EVs trigger autol-
ogous ﬁbroblast-like synoviocytes to produce and secrete inﬂammatory
mediators including monocyte chemoattractant protein-1, IL-8, IL-6,
RANTES (regulated on activation, normal T cell expressed and secreted),
ICAM-1 (Intercellular Adhesion Molecule-1) and VEGF.54 Although
PMVswere also reported to be present in synovial ﬂuid, there is no con-
sensus on this matter yet.18,74 PMVs can also activatemonocytes via the
RANTES pathway, thereby inducing monocyte migration and recruit-
ment to sites of inﬂammation.75
MVs from neutrophils trigger secretion of transforming growth
factor β1, a potent inhibitor of macrophage activation, by human
macrophages, and thus elicit an anti-inﬂammatory activity.76 These
MVs also contain the anti-inﬂammatory protein annexin 1,77 and
such vesicles inhibit the inﬂammatory response of macrophages to
bacterial lipopolysaccharide.76
PMVs orchestrate immune responses by delivering CD154, also
known as CD40 ligand or CD40L, to initiate and propagate the adaptive
immune response via CD4+ T cells.78 Also tumor-derived exosomes can
modulate the immune response by affecting the differentiation of anti-
gen presenting cells, such as dendritic cells (DCs). Differentiation of
monocytes to DCs is impaired by tumor-derived exosomes isolated
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also promote the generation of a myeloid immunosuppressive cell
subset (CD14+HLA-DR−/low).29 In addition, exosomes from tumor
cells can also down-regulate the immune response against the tumor
by inducing apoptosis of activated T cells via the Fas/Fas ligand path-
way. Wieckowski et al.79 demonstrated that EVs from tumor cells but
not EVs from DCs isolated from sera of head and neck squamous cell
carcinoma and melanoma patients are enriched in Fas ligand. These
EVs induced the proliferation of CD4+CD25+FOXP3+ T regulatory
cells and suppressed CD8+ effector T cells in vitro. The suppression ef-
fect is mediated by Fas/FasL interactions. Thus, tumor-derived vesicles
may contribute to tumor growth and development by interfering with
the anti-tumor immune response via various mechanisms.5.5. Coagulation
Tissue factor (TF) initiates coagulation. TF is not expressed and pro-
duced by cells within the blood under physiological conditions, but is
constitutively expressed and produced by extravascular cells such as
smooth muscle cells. Under pathological conditions, however, sepsis,
ECs and monocytes, and perhaps neutrophils, can produce coagulant
TF.80–85 Reports of the presence, cellular source and coagulant activity
of TF in blood are controversial. In 1999 Giesen et al.86 demonstrated
the presence of TF antigen and coagulation activity on monocytes, neu-
trophils, and cell-derived vesicles (also named ‘blood-borne TF’) in
blood and plasma of healthy individuals. However, others showed
that the concentration of coagulation active TF either in blood or plasma
from healthy individuals does not exceed 20 fmol/l.87 Moreover, it
seems unlikely that such concentrations of vesicle-exposed coagulant
TF can be present in vivo under normal conditions because in vitro the
addition of (sub)picomolar concentrations of active TF induces the
clotting of blood or plasma within minutes.88,89 In fact, the presence
of detectable levels of coagulant TF in blood has been associatedwith in-
travascular bleeding and thrombosis. Blood from a patient withmenin-
gococcal septic shock, who suffered and probably also died from
disseminated intravascular coagulation, contained a large number of
monocyte-derived vesicles exposing highly coagulant TF.45 Further-
more increased levels of coagulant TF exposed on circulating vesicles
are present in blood from cancer patients who developed venous
thromboembolism (VTE), suggesting that such vesicles may contribute
to thrombotic events in such patients. One must bear in mind that TF
can also be present in a non-coagulant form on vesicles.13,80,90 This is
likely to be themain form of TF in the circulating blood. In contrast, ves-
icles exposing highly coagulant TF are present in human wound blood,
where they are likely to play a physiological role in hemostasis.91,92
In contrast to blood, saliva and urine of healthy humans contain high
numbers of vesicles exposing coagulant TF. Addition of saliva shortens
the clotting time of autologous plasma and whole blood.51 EVs isolated
from saliva expose TF and initiate TF/factor VII-mediated coagulation,
illustrating that saliva and urine, but not blood, contain vesicles expos-
ing coagulant TF under physiological conditions.
MVs exposing coagulant TF have been reported in various patho-
logical conditions such as sickle cell disease (SCD), acute coronary
syndrome (ACS), essential thrombocythemia and cancer, but often
the results from such studies are difﬁcult to compare to each other.
For example, plasma from SCD patients was reported to contain
endothelial- and monocyte-derived MVs exposing TF, and these
MVs were shown to be procoagulant.93 In contrast, we detected
only platelet and erythrocyte-derived MVs in plasma of SCD patients,
and the procoagulant state was associated with activation of factor XI
and not with extrinsic coagulation activation.94 The isolation condi-
tions of vesicles in the two studies, however, were markedly different,
and are likely to affect the results.
In most but not all studies, elevated levels of MVs of endothelial or-
igin are reported in plasma from ACS patients compared to non-ACSpatients.95,96 To which extent these endothelial MVs contribute to the
hypercoagulable status of these patients, however, is unknown.
MVs isolated from blood of patientswith essential thrombocythemia,
a chronicmyeloproliferative disease that is characterized by an increased
risk of both arterial and venous thrombosis, are mostly derived from
platelets and ECs. The MVs in these patients are thought to contribute
to the hypercoagulable state that is observed in vivo.97
Plasma from patients with certain types of cancer contains higher
numbers of vesicles than plasma from healthy subjects.13,14,98 Fur-
thermore, MVs exposing coagulant TF in blood of cancer patients
have been associated not only with thrombosis but also with disease
progression.13,15 Interestingly, in some cancer patients with a detect-
able level of coagulant TF present within the blood, a minor fraction of
MVs exposes the epithelial marker, MUC-1.13 To which extent these
MUC-1-expressing vesicles, i.e. vesicles likely to originate from the
tumor, are exposing coagulant TF and to which extent such vesicles
are associated with development of VTE, however, remain to be de-
termined.99 Furthermore, tumor cells may elicit a host response that
leads to expression of TF by monocytes and possibly ECs, and to the
shedding of MVs bearing TF. Recently, in a study comprising over
200 cancer patients, we found a subpopulation of vesicles in one pa-
tient exposing TF, VE-cadherin (CD144) and E-selectin (CD62e),
both speciﬁc markers of endothelial origin. How much TF exposed
by this subpopulation is coagulant or how TF contributes to coagula-
tion activation in vivo has not been investigated yet (A. Kleinjan, MD,
personal communication). One has to bear in mind that TF can also
induce angiogenesis and transmembrane signaling, each processes
important for cancer growth and development. To which extent
vesicle-exposed TF contributes to such functions in cancer patients
is unknown.
It is still unknown whether exosomes are coagulant. This is a rele-
vant question because most vesicles present in body ﬂuids are within
the size range of exosomes rather than of MVs, and thus may have a
relatively large contribution to coagulation because formation of
tenase and prothrombinase complexes requires a membrane surface
which both MVs and exosomes could provide. The membrane surface
has to expose negatively charged lipids such as PS to enable the for-
mation of the coagulation factor complexes and the PS can be
detected by binding of annexin V. Heijnen et al.20 showed that only
a relatively low number of exosomes, supposed to originate from
platelets, bound annexin V. Furthermore, MVs but not exosomes
bound factor X and prothrombin in this study. This would indicate
that exosomes are not a mainly determinant in the propagation of
the coagulation process once the coagulation system has been acti-
vated. In contrast, Davila et al.100 showed that exosomes, deﬁned as
vesicles with a diameter of less than 100 nm, contribute to the overall
procoagulant activity of tumor cell derived vesicles. They showed that
approximately 20% of the TF coagulant activity was still present after
ﬁltration through a 0.1 μm ﬁlter, which would indicate a role for
exosomes in coagulation activation. Unfortunately, they did not in-
vestigate whether ﬁltration enables removal of all vesicles larger
than 0.1 μm, or whether larger vesicles are fragmented by such a pro-
cedure, making the distinction between exosomes and small MVs
uncertain.
5.6. Waste management
Vesicles act at two levels regarding waste management. Vesicles
can contain redundant intracellular components, thus acting as cellu-
lar waste disposal bags by their extrusion from the cell. In turn, such
vesicles may be removed from the circulation by phagocytosis by
other cells. It is tempting to speculate that EVs containing cellular
waste are especially equipped to facilitate their clearance, e.g. by ex-
posing PS, thereby becoming easy targets for phagocytes. There is ev-
idence that the spleen is involved in the clearance of MVs in vivo.100
Thirty minutes after injection of PS-exposing MVs from breast or
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decreased by 72% and 90%, respectively, becoming undetectable 2 h
after injection. Already 5 min after injection, the TF antigen was de-
tectable in the spleen. In contrast, in splenectomized mice most of
the human TF antigen was still detectable 30 min after injection,
and 30% of the splenectomized mice did not survive 2 h after injec-
tion. In humans, clearance of circulating vesicles exposing coagulant
TF is extremely fast and efﬁcient. We showed that human wound
(pericardial) blood from patients undergoing open heart surgery con-
tains exceptionally high levels of coagulant TF-exposing vesicles that
trigger coagulation in vitro91 and thrombus formation in vivo.92
When this wound blood is retransfused, the TF-coagulant activity be-
comes undetectable in peripheral blood already after 20–30 min, re-
vealing that also in humans clearance of vesicles must be very
efﬁcient.101
In pathological conditions, thewastemanagementmay not function
properly. This could happen because of the failure of the phagocytes
to recognize the danger signal102,103 or because these phagocytes
are impaired (apoptotic/necrotic).104–106 The consequence is that EVs
containing redundant and unwanted biomolecules are not rapidly
cleared from the circulation. Thus, these EVs are likely to play a role in
the pathological conditions. Monocytes are phagocytes which expose
a PS-speciﬁc receptor that recognizes PS-exposing vesicles.107 In an in
vitro study, human monocytic leukemia cells (THP-1 cells) showed
signs of apoptosis or possibly even necrosis after incubation with
PS-exposing PMVs containing caspase 3.106 This study supports the no-
tion that decreased clearance of vesicles from the circulation may be
detrimental.
6. Potential biomarkers and novel therapies
EVs are potential biomarkers for detection of diseases. Total num-
bers and/or numbers of certain subsets of EVs in body ﬂuids may be
used to predict the presence of a disease, or a risk factor of developing
a disease. Recently, increased numbers of several types of EVs were
shown to increase the Framingham risk score (FRS), a risk assessment
tool to estimate a patient's 10-year risk of developing CVD.108–110
These results are promising and imply that more prospective studies
are needed to further investigate the prognostic value of EVs in indi-
viduals at risk for CVD.
In cancer patients with VTE, the coagulant activity of TF associated
with MVs isolated from platelet-poor plasma is markedly increased
compared to the cancer patients without VTE.13,98 These ﬁndings sug-
gest that MVs associated with coagulant TF in cancer patients may
predict thrombotic events in patients at risk of developing VTE.
EGFRvIII promotes the expression of the proangiogenic protein
IL-8 through the NF-κB pathway.62 EGFRvIII mRNA was present not
only in resected glioma tissue but also detectable in exosomes isolat-
ed from serum of 7 out of 25 glioblastoma patients.30 Thus, measuring
EGFRvIII mRNA in vesicles may provide clinically relevant informa-
tion on tumor presence, tumor progression, and response to therapy.
Not only blood or fractions thereof, but also other body ﬂuids may be
a useful source of vesicular biomarkers. For example, aquaporin-2, ex-
posed by exosomes isolated from urine, may be a biomarker for renal
and systemic disease.50 Exosomes isolated from urine were shown to
contain the mRNA encoding two known prostate cancer biomarkers,
PCA3 and TMPRSS2: ERG, and both mRNAs can be transferred to
platelets.69 Thus, extraction of mRNA from urine or platelets may pro-
vide a useful means for prostate cancer diagnosis.
Vesicles also offer therapeutic applications. For example, the adhe-
sion of hematopoietic stem–progenitor cells (HSPC) to the endothelium
is signiﬁcantly improved in the presence of PMVs, thereby supporting
engraftment after stem cell transplantation in lethally irradiated
mice.111 MVs derived fromMSCsmay provide a future (adjuvant) ther-
apy for acute renal injury112 because intravenous administration of
MSC-derived MVs improves the recovery of glycerol induced-acuterenal injury in SCID mice.113 Exosomes from IL-10-treated immature
DCs suppress inﬂammatory and autoimmune responses.114 This type
of exosome may therefore become a suitable therapy for arthritis. An-
other interesting clinical application is exosome-based immunothera-
py. The initial studies by using DC-derived exosomes (“dexosomes”)
loaded with tumor peptides showed that “dexosomes” are capable of
priming cytotoxic T cells and inducing tumor rejection in mice.115
Dexosomes also promote NK cell activation in immunocompetent
mice and NK cell-dependent anti-tumor effects.115 Based on these
results, clinical trials are ongoing.116 There are several strategies to
use exosomes as a (therapeutic) vaccine. Tumor-derived exosomes
carrying tumor antigens and plasmacytoma cell-derived exosomes
may be used to induce tumor-speciﬁc immunity and thus to prevent
tumor development.1177. Preparation and measurement of EVs
Despite the extensive studies on EVs, until now there are no pro-
tocols available for standardized collection, isolation and storage of
EVs. Such standardized protocols are important to be able to com-
pare results between laboratories. Despite the fact that blood is
probably our most complex body ﬂuid, EVs present in or isolated
from blood or fractions thereof have been most extensively studied
so far. Although there are several recommendations regarding the
collection of blood with regard to EVs,118 for other body ﬂuids no
protocols are available. In most studies EVs have been isolated from
body ﬂuids by differential centrifugation.3,47 Differential centrifuga-
tion involves multiple sequential centrifugation steps where in each
step the centrifugal force is increased to separate smaller and less
dense components from the previous step. Another type of separa-
tion by means of centrifugation is density-gradient ultracentrifuga-
tion, which separates vesicles based on density.20,119 Although
different types of vesicles have been distinguished based on densi-
ty,3,20,41 differences in density are likely too small to allow full sepa-
ration of EV species. Differential centrifugation and density-gradient
centrifugation protocols are unlikely to isolate only a single type of
vesicle. Immunoafﬁnity-based assays, usually coated with a speciﬁc
CD-antibody, are also used.84,120 Theoretically, this method isolates
only one subpopulation of vesicles. Unfortunately, in daily practice
successful isolation and puriﬁcation of a single population with an
acceptable recovery by this technique are usually very difﬁcult. Ide-
ally, EVs are measured directly in freshly collected samples, but in a
clinical setting this is hardly feasible at present. When samples are
frozen and thawed before analysis, concentrations and exposure of
PS can markedly increase in samples containing PMVs.35,118
As EVs may expose one or more surface antigens of their parent
cell, the cellular origin of EVs can be assessed by using antibodies di-
rected against such cell-type speciﬁc surface antigens. Flow cytome-
try (FCM) is still commonly used to estimate the number of EVs.
Due to the fact that the refractive index of vesicles is low, only the
larger vesicles will be detected as single vesicles and the smaller ves-
icles will be detected only as a swarm.121 Thus, FCM will underesti-
mate the number and concentration of vesicles. Although many
researchers use annexin V to identify or isolate MVs, PS exposure by
MVs is still ambiguous because exposure of PS can be due to isolation
and handling procedures such as centrifugation and storage.33,35 Fur-
thermore, the binding of annexin V to MVs depends on the calcium
concentration and the membrane PS content,33,122 and staining of
PS-exposing MVs with lactadherin, a milk fat globule-epidermal
growth factor VIII (MFG-E8), may be more sensitive to small changes
in PS exposure than annexin V.34,123 Because the binding of lactadherin
to PS is calcium independent, lactadherin can be used to detect PS-
exposing MVs directly in citrate- or EDTA-anticoagulated plasma
samples, whereas PS detection by annexin V is calcium dependent
and can therefore not be performed in those materials.
37Y. Yuana et al. / Blood Reviews 27 (2013) 31–39Other techniques such as TEM,20–22,40 capture assays22,84,124 and
atomic forcemicroscopy (AFM)23,125–127 can also be used in combination
with speciﬁc antibodies. However, the speciﬁcity, afﬁnity, and whether
the antibody tends to form aggregates, are all important considerations
in selecting the antibody of choice.118,128
As regards techniques such as NTA,129–133 AFM125,127,134,135 and
RPS,121 single EVs can be detected directly in body ﬂuids or buffers.
Based on data obtained by these techniques, EVs in solution are
reported to be spherical and to have diameters ranging between 20
and 600 nm, with a mean diameter of 50 nm.21,125,132 But again,
things are complicated. One has to keep in mind that plasma also con-
tains high concentrations of lipoprotein particles, and techniques
such as NTA or RPS cannot distinguish between EVs and lipoprotein
particles. The body ﬂuid containing EVs, the pre-analytical conditions
of body ﬂuid collection and sample preparation, and the methodology
used to measure the EVs all considerably inﬂuence the number and
size distribution of EVs.35,118 Interestingly, by using AFM combined
with microﬂuidics, Ashcroft et al.135 showed that the size distribu-
tions of CD41-exposing vesicles in fresh plasma before and after iso-
lation are comparable, indicating that the size distribution was
unaffected by the isolation procedure used in that study.
Recently, a novel high resolution FCM-basedmethodwas developed
to detect single exosome-sized particles based on ﬂuorescence.
Although this methodology offers the opportunity to detect single
exosome-sized vesicles directly in solution, unbound antibody has to
be removed from vesicles using gradient centrifugation, making this
technology not or hardly useful in a clinical setting.136,137
8. Conclusions and future directions
The underlying mechanisms of the formation of EVs are still
largely unexplored, and the distinction or isolation of puriﬁed EV
species is still a goal to be attained. Nevertheless, the formation and
release of EVs seem to relate to cellular homeostasis by balancing
intra- and extracellular signals. Clearly, EVs are likely to contribute to
physiology and pathology. There is still no consensus on EV classiﬁca-
tion which is likely related to the lack of sensitive methodologies on
the detection of EVs. Currently, new technologies which provide sensi-
tive detection and reliable measurements of EVs are being developed.
These new technologies as well as the preparation of EVs from body
ﬂuids also need to be standardized to make the measurements of EVs
feasible in the clinical settings. In the near future, EVs may serve as
potential clinical biomarkers for diagnosis and prognosis, and therapy
of certain diseases.
Practice points
• All human body ﬂuids including blood, urine, saliva, mother milk,
and cerebrospinal and synovial ﬂuid contain surprising numbers
of extracellular vesicles (EVs) which are now thought to contribute
to both physiology and pathology.
• EVs carry biomolecules such as proteins, second messengers, and
genetic information for delivery and transfer only to dedicated tar-
get cells, and therefore are capable of changing the composition and
function of target (recipient) cells.
• Increased total numbers and/or numbers of certain subsets of EVs in
body ﬂuids may be used to predict the presence of a disease, or a
risk factor of developing a disease.
• EVs also offer therapeutic applications, i.e. tumor- and dendritic
cell-derived exosomes to induce tumor-speciﬁc immunity and
thus to prevent tumor development.
Research agenda
• The underlying mechanisms of the formation of EVs are still largely
unexplored.• There is still no consensus on EV classiﬁcation which is likely relat-
ed to the lack of suitable isolation/puriﬁcation protocols of single
type of EVs.
• There are no protocols available for standardized collection, isola-
tion and storage of EVs.
• New technologies which allow sensitive detection and reliable
measurements of EVs also need to be standardized to make the
measurements of EVs feasible in the clinical settings.Conﬂict of interest
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of interest.
References
[1] Lee EY, Choi DY, Kim DK, Kim JW, Park JO, Kim S, et al. Gram-positive bacteria pro-
duce membrane vesicles: proteomics-based characterization of Staphylococcus
aureus-derived membrane vesicles. Proteomics 2009;9(24):5425–36.
[2] Deatherage BL, Cookson BT. Membrane vesicle release in bacteria, eukaryotes,
and archaea: a conserved yet underappreciated aspect of microbial life. Infect
Immun 2012;80(6):1948–57.
[3] Van Der Pol E, Boing AN, Harrison P, Sturk A, Nieuwland R. Classiﬁcation, functions,
and clinical relevance of extracellular vesicles. Pharmacol Rev 2012;64(3):
676–705.
[4] Gyorgy B, Szabo TG, Pasztoi M, Pal Z, Misjak P, Aradi B, et al. Membrane vesicles,
current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci
2011;68(16):2667–88.
[5] Zwaal RF, Schroit AJ. Pathophysiologic implications of membrane phospholipid
asymmetry in blood cells. Blood 1997;89(4):1121–32.
[6] Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and func-
tion. Nat Rev Immunol 2002;2(8):569–79.
[7] Flaumenhaft R. Formation and fate of platelet microparticles. Blood Cells Mol Dis
2006;36(2):182–7.
[8] Zwaal RF, Comfurius P, Bevers EM. Surface exposure of phosphatidylserine in
pathological cells. Cell Mol Life Sci 2005;62(9):971–88.
[9] Frey B, Gaipl US. The immune functions of phosphatidylserine in membranes of
dying cells and microvesicles. Semin Immunopathol 2011;33(5):497–516.
[10] Safaei R, Larson BJ, Cheng TC, Gibson MA, Otani S, Naerdemann W, et al. Abnor-
mal lysosomal trafﬁcking and enhanced exosomal export of cisplatin in
drug-resistant human ovarian carcinoma cells. Mol Cancer Ther 2005;4(10):
1595–604.
[11] Shedden K, Xie XT, Chandaroy P, Chang YT, Rosania GR. Expulsion of small mol-
ecules in vesicles shed by cancer cells: association with gene expression and
chemosensitivity proﬁles. Cancer Res 2003;63(15):4331–7.
[12] Mathivanan S, Ji H, Simpson RJ. Exosomes: extracellular organelles important in
intercellular communication. J Proteomics 2010;73(10):1907–20.
[13] Tesselaar ME, Romijn FP, van der Linden IK, Prins FA, Bertina RM, Osanto S.
Microparticle-associated tissue factor activity: a link between cancer and thrombo-
sis? J Thromb Haemost 2007;5(3):520–7.
[14] Zwicker JI, Liebman HA, Neuberg D, Lacroix R, Bauer KA, Furie BC, et al.
Tumor-derived tissue factor-bearing microparticles are associated with venous
thromboembolic events in malignancy. Clin Cancer Res 2009;15(22):6830–40.
[15] Langer F, Spath B, Haubold K, Holstein K, Marx G, Wierecky J, et al. Tissue factor
procoagulant activity of plasma microparticles in patients with cancer-associated
disseminated intravascular coagulation. Ann Hematol 2008;87(6):451–7.
[16] VanWijk MJ, VanBavel E, Sturk A, Nieuwland R. Microparticles in cardiovascular
diseases. Cardiovasc Res 2003;59(2):277–87.
[17] Shantsila E, Kamphuisen PW, Lip GY. Circulating microparticles in cardiovascular
disease: implications for atherogenesis and atherothrombosis. J Thromb Haemost
2010;8(11):2358–68.
[18] Berckmans RJ, Nieuwland R, Tak PP, Boing AN, Romijn FP, Kraan MC, et al.
Cell-derived microparticles in synovial ﬂuid from inﬂamed arthritic joints sup-
port coagulation exclusively via a factor VII-dependent mechanism. Arthritis
Rheum 2002;46(11):2857–66.
[19] Knijff-Dutmer EA, Koerts J, Nieuwland R, Kalsbeek-Batenburg EM, van de Laar
MA. Elevated levels of platelet microparticles are associated with disease activity
in rheumatoid arthritis. Arthritis Rheum 2002;46(6):1498–503.
[20] Heijnen HF, Schiel AE, Fijnheer R, Geuze HJ, Sixma JJ. Activated platelets release two
types of membrane vesicles: microvesicles by surface shedding and exosomes
derived from exocytosis of multivesicular bodies and alpha-granules. Blood
1999;94(11):3791–9.
[21] Van Der Pol E, Hoekstra AG, Sturk A, Otto C, Van Leeuwen TG, Nieuwland R. Op-
tical and non-optical methods for detection and characterization of microparti-
cles and exosomes. J Thromb Haemost 2010;8(12):2596–607.
[22] Aras O, Shet A, Bach RR, Hysjulien JL, Slungaard A, Hebbel RP, et al. Induction of
microparticle- and cell-associated intravascular tissue factor in human
endotoxemia. Blood 2004;103(12):4545–53.
[23] Salzer U, Hinterdorfer P, Hunger U, Borken C, Prohaska R. Ca(++)-dependent
vesicle release from erythrocytes involves stomatin-speciﬁc lipid rafts, synexin
(annexin VII), and sorcin. Blood 2002;99(7):2569–77.
38 Y. Yuana et al. / Blood Reviews 27 (2013) 31–39[24] Del CI, Shrimpton CN, Thiagarajan P, Lopez JA. Tissue-factor-bearing microvesicles
arise from lipid rafts and fuse with activated platelets to initiate coagulation.
Blood 2005;106(5):1604–11.
[25] Salzer U, Zhu R, Luten M, Isobe H, Pastushenko V, Perkmann T, et al. Vesicles gen-
erated during storage of red cells are rich in the lipid raft marker stomatin.
Transfusion 2008;48(3):451–62.
[26] Duijvesz D, Luider T, Bangma CH, Jenster G. Exosomes as biomarker treasure
chests for prostate cancer. Eur Urol 2011;59(5):823–31.
[27] Bernimoulin M, Waters EK, Foy M, Steele BM, Sullivan M, Falet H, et al. Differential
stimulation of monocytic cells results in distinct populations of microparticles.
J Thromb Haemost 2009;7(6):1019–28.
[28] Jimenez JJ, Jy W, Mauro LM, Soderland C, Horstman LL, Ahn YS. Endothelial cells
release phenotypically and quantitatively distinct microparticles in activation
and apoptosis. Thromb Res 2003;109(4):175–80.
[29] Valenti R, Huber V, Filipazzi P, Pilla L, SovenaG, Villa A, et al. Human tumor-released
microvesicles promote the differentiation of myeloid cells with transforming
growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer
Res 2006;66(18):9290–8.
[30] Skog J, Wurdinger T, van RS, Meijer DH, Gainche L, Sena-Esteves M, et al. Glioblas-
toma microvesicles transport RNA and proteins that promote tumour growth and
provide diagnostic biomarkers. Nat Cell Biol 2008;10(12):1470–6.
[31] Piccin A, Murphy WG, Smith OP. Circulating microparticles: pathophysiology
and clinical implications. Blood Rev 2007;21(3):157–71.
[32] Satta N, Toti F, Fressinaud E, Meyer D, Freyssinet JM. Scott syndrome: an inherited
defect of the procoagulant activity of platelets. Platelets 1997;8(2–3):117–24.
[33] Connor DE, Exner T, Ma DD, Joseph JE. The majority of circulating platelet-derived
microparticles fail to bind annexin V, lack phospholipid-dependent procoagulant
activity and demonstrate greater expression of glycoprotein Ib. Thromb Haemost
2010;103(5):1044–52.
[34] Perez-Pujol S, Marker PH, Key NS. Platelet microparticles are heterogeneous and
highly dependent on the activation mechanism: studies using a new digital ﬂow
cytometer. Cytometry A 2007;71(1):38–45.
[35] Ayers L, Kohler M, Harrison P, Sargent I, Dragovic R, Schaap M, et al. Measure-
ment of circulating cell-derived microparticles by ﬂow cytometry: sources of
variability within the assay. Thromb Res 2011;127(4):370–7.
[36] Pant S, Hilton H, Burczynski ME. The multifaceted exosome: biogenesis, role in
normal and aberrant cellular function, and frontiers for pharmacological and
biomarker opportunities. Biochem Pharmacol 2012;83(11):1484–94.
[37] Record M, Subra C, Silvente-Poirot S, Poirot M. Exosomes as intercellular
signalosomes and pharmacological effectors. Biochem Pharmacol 2011;81(10):
1171–82.
[38] Bellingham SA, Guo BB, Coleman BM, Hill AF. Exosomes: vehicles for the transfer
of toxic proteins associated with neurodegenerative diseases? Front Physiol
2012;3:124.
[39] Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F, et al. Ceramide
triggers budding of exosome vesicles into multivesicular endosomes. Science
2008;319(5867):1244–7.
[40] Lasser C, Eldh M, Lotvall J. Isolation and characterization of RNA-containing
exosomes. J Vis Exp 2012;59:e3037.
[41] Thery C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune re-
sponses. Nat Rev Immunol 2009;9(8):581–93.
[42] Taylor DD, Gercel-Taylor C. Exosomes/microvesicles: mediators of cancer-
associated immunosuppressive microenvironments. Semin Immunopathol
2011;33(5):441–54.
[43] Savina A, Furlan M, Vidal M, Colombo MI. Exosome release is regulated by a
calcium-dependent mechanism in K562 cells. J Biol Chem 2003;278(22):
20083–90.
[44] Burnier L, Fontana P, Kwak BR, Angelillo-Scherrer A. Cell-derived microparticles
in haemostasis and vascular medicine. Thromb Haemost 2009;101(3):439–51.
[45] Nieuwland R, Berckmans RJ, McGregor S, Boing AN, Romijn FP, Westendorp RG,
et al. Cellular origin and procoagulant properties of microparticles in meningo-
coccal sepsis. Blood 2000;95(3):930–5.
[46] Lasser C, Alikhani VS, Ekstrom K, EldhM, Paredes PT, Bossios A, et al. Human saliva,
plasma and breast milk exosomes contain RNA: uptake by macrophages. J Transl
Med 2011;9:9.
[47] Vlassov AV, Magdaleno S, Setterquist R, Conrad R. Exosomes: current knowledge
of their composition, biological functions, and diagnostic and therapeutic poten-
tials. Biochim Biophys Acta 2012;1820(7):940–8.
[48] Keller S, Rupp C, Stoeck A, Runz S, Fogel M, Lugert S, et al. CD24 is a marker of
exosomes secreted into urine and amniotic ﬂuid. Kidney Int 2007;72(9):
1095–102.
[49] Pisitkun T, Shen RF, Knepper MA. Identiﬁcation and proteomic proﬁling of
exosomes in human urine. Proc Natl Acad Sci U S A 2004;101(36):13368–73.
[50] Miranda KC, Bond DT, McKee M, Skog J, Paunescu TG, Da SN, et al. Nucleic acids
within urinary exosomes/microvesicles are potential biomarkers for renal dis-
ease. Kidney Int 2010;78(2):191–9.
[51] Berckmans RJ, Sturk A, van Tienen LM, Schaap MC, Nieuwland R. Cell-derived
vesicles exposing coagulant tissue factor in saliva. Blood 2011;117(11):3172–80.
[52] Street JM, Barran PE,Mackay CL,Weidt S, Balmforth C,Walsh TS, et al. Identiﬁcation
and proteomic proﬁling of exosomes in human cerebrospinal ﬂuid. J Transl Med
2012;10:5.
[53] Turola E, Furlan R, Bianco F, Matteoli M, Verderio C. Microglial microvesicle se-
cretion and intercellular signaling. Front Physiol 2012;3:149.
[54] Berckmans RJ, Nieuwland R, KraanMC, SchaapMC, Pots D, Smeets TJ, et al. Synovial
microparticles from arthritic patientsmodulate chemokine and cytokine release by
synoviocytes. Arthritis Res Ther 2005;7(3):R536–44.[55] Zhang HG, Liu C, Su K, Yu S, Zhang L, Zhang S, et al. A membrane form of TNF-alpha
presented by exosomes delays T cell activation-induced cell death. J Immunol
2006;176(12):7385–93.
[56] Yang C, Mwaikambo BR, Zhu T, Gagnon C, Laﬂeur J, Seshadri S, et al. Lymphocytic
microparticles inhibit angiogenesis by stimulating oxidative stress and negative-
ly regulating VEGF-induced pathways. Am J Physiol Regul Integr Comp Physiol
2008;294(2):R467–76.
[57] Wysoczynski M, Ratajczak MZ. Lung cancer secreted microvesicles: underappreciat-
edmodulators ofmicroenvironment in expanding tumors. Int J Cancer 2009;125(7):
1595–603.
[58] Mostefai HA, Andriantsitohaina R, Martinez MC. Plasma membrane microparticles
in angiogenesis: role in ischemic diseases and in cancer. Physiol Res 2008;57(3):
311–20.
[59] Kim HK, Song KS, Chung JH, Lee KR, Lee SN. Platelet microparticles induce angio-
genesis in vitro. Br J Haematol 2004;124(3):376–84.
[60] Brill A, Dashevsky O, Rivo J, Gozal Y, Varon D. Platelet-derived microparticles in-
duce angiogenesis and stimulate post-ischemic revascularization. Cardiovasc
Res 2005;67(1):30–8.
[61] Boulanger CM, Tedgui A. Dying for attention: microparticles and angiogenesis.
Cardiovasc Res 2005;67(1):1–3.
[62] Bonavia R, Inda MM, Vandenberg S, Cheng SY, Nagane M, Hadwiger P, et al.
EGFRvIII promotes glioma angiogenesis and growth through the NF-kappaB,
interleukin-8 pathway. Oncogene 2012;31(36):4054–66.
[63] Bussolati B, Grange C, Camussi G. Tumor exploits alternative strategies to
achieve vascularization. FASEB J 2011;25(9):2874–82.
[64] Taraboletti G, D'Ascenzo S, Borsotti P, Giavazzi R, Pavan A, Dolo V. Shedding of
the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane
vesicle-associated components by endothelial cells. Am J Pathol 2002;160(2):
673–80.
[65] Janowska-Wieczorek A, Wysoczynski M, Kijowski J, Marquez-Curtis L, Machalinski
B, Ratajczak J, et al.Microvesicles derived fromactivatedplatelets inducemetastasis
and angiogenesis in lung cancer. Int J Cancer 2005;113(5):752–60.
[66] Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells
and their microenvironment. Blood 2006;107(5):1761–7.
[67] Janowska-Wieczorek A, Marquez-Curtis LA, Wysoczynski M, Ratajczak MZ. En-
hancing effect of platelet-derived microvesicles on the invasive potential of
breast cancer cells. Transfusion 2006;46(7):1199–209.
[68] Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G,
et al. Melanoma exosomes educate bone marrow progenitor cells toward a
pro-metastatic phenotype through MET. Nat Med 2012;18(6):883–91.
[69] Nilsson RJ, Balaj L, Hulleman E, van RS, Pegtel DM,WalravenM, et al. Blood platelets
contain tumor-derived RNA biomarkers. Blood 2011;118(13):3680–3.
[70] Sheldon H, Heikamp E, Turley H, Dragovic R, Thomas P, Oon CE, et al. Newmecha-
nism for Notch signaling to endothelium at a distance by Delta-like 4 incorporation
into exosomes. Blood 2010;116(13):2385–94.
[71] Tatischeff I. Cell-derived microvesicles and antitumoral multidrug resistance. C R
Biol 2012;335(2):103–6.
[72] BebawyM, Combes V, Lee E, Jaiswal R, Gong J, Bonhoure A, et al. Membranemicro-
particlesmediate transfer of P-glycoprotein to drug sensitive cancer cells. Leukemia
2009;23(9):1643–9.
[73] Bruno S, Grange C, Collino F, Deregibus MC, Cantaluppi V, Biancone L, et al.
Microvesicles derived from mesenchymal stem cells enhance survival in a lethal
model of acute kidney injury. PLoS One 2012;7(3):e33115.
[74] Boilard E, Nigrovic PA, Larabee K,Watts GF, Coblyn JS, Weinblatt ME, et al. Platelets
amplify inﬂammation in arthritis via collagen-dependentmicroparticle production.
Science 2010;327(5965):580–3.
[75] Mause SF, von HP, Zernecke A, Koenen RR, Weber C. Platelet microparticles: a
transcellular delivery system for RANTES promoting monocyte recruitment on
endothelium. Arterioscler Thromb Vasc Biol 2005;25(7):1512–8.
[76] Gasser O, Schifferli JA. Activated polymorphonuclear neutrophils dissemi-
nate anti-inﬂammatory microparticles by ectocytosis. Blood 2004;104(8):
2543–8.
[77] Dalli J, Norling LV, Renshaw D, Cooper D, Leung KY, Perretti M. Annexin 1 medi-
ates the rapid anti-inﬂammatory effects of neutrophil-derived microparticles.
Blood 2008;112(6):2512–9.
[78] Sprague DL, Elzey BD, Crist SA, Waldschmidt TJ, Jensen RJ, Ratliff TL. Platelet-
mediated modulation of adaptive immunity: unique delivery of CD154 signal
by platelet-derived membrane vesicles. Blood 2008;111(10):5028–36.
[79] Wieckowski EU, Visus C, Szajnik M, Szczepanski MJ, Storkus WJ, Whiteside TL.
Tumor-derivedmicrovesicles promote regulatory T cell expansion and induce apo-
ptosis in tumor-reactive activated CD8+ T lymphocytes. J Immunol 2009;183(6):
3720–30.
[80] Bach RR. Tissue factor encryption. Arterioscler Thromb Vasc Biol 2006;26(3):
456–61.
[81] Simak J, Holada K, Vostal JG. Release of annexin V-binding membrane micropar-
ticles from cultured human umbilical vein endothelial cells after treatment with
camptothecin. BMC Cell Biol 2002;3:11.
[82] Sabatier F, Roux V, Anfosso F, Camoin L, Sampol J, gnat-George F. Interaction of
endothelial microparticles with monocytic cells in vitro induces tissue factor-
dependent procoagulant activity. Blood 2002;99(11):3962–70.
[83] Brodsky SV, Malinowski K, Golightly M, Jesty J, GoligorskyMS. Plasminogen activa-
tor inhibitor-1 promotes formation of endothelialmicroparticleswith procoagulant
potential. Circulation 2002;106(18):2372–8.
[84] Yuana Y, Osanto S, Bertina RM. Use of immuno-magnetic beads for direct capture
of nanosized microparticles from plasma. Blood Coagul Fibrinolysis 2012;23(3):
244–50.
39Y. Yuana et al. / Blood Reviews 27 (2013) 31–39[85] Henriksson CE, Klingenberg O, Ovstebo R, Joo GB, Westvik AB, Kierulf P. Dis-
crepancy between tissue factor activity and tissue factor expression in
endotoxin-induced monocytes is associated with apoptosis and necrosis.
Thromb Haemost 2005;94(6):1236–44.
[86] Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, et al. Blood-borne
tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A 1999;96(5):
2311–5.
[87] Butenas S, Orfeo T, Mann KG. Tissue factor in coagulation. Which? Where?
When? Arterioscler Thromb Vasc Biol 2009;29(12):1989–96.
[88] Berckmans RJ, Neiuwland R, Boing AN, Romijn FP, Hack CE, Sturk A. Cell-derived
microparticles circulate in healthy humans and support low grade thrombin gener-
ation. Thromb Haemost 2001;85(4):639–46.
[89] Butenas S, Mann KG. Active tissue factor in blood? Nat Med 2004;10(11):
1155–6.
[90] Versteeg HH, RufW. Tissue factor coagulant function is enhanced by protein-disulﬁde
isomerase independent of oxidoreductase activity. J Biol Chem 2007;282(35):
25416–24.
[91] Nieuwland R, Berckmans RJ, Rotteveel-Eijkman RC, Maquelin KN, Roozendaal KJ,
Jansen PG, et al. Cell-derived microparticles generated in patients during cardio-
pulmonary bypass are highly procoagulant. Circulation 1997;96(10):3534–41.
[92] Biro E, Sturk-Maquelin KN, Vogel GM, Meuleman DG, Smit MJ, Hack CE, et al.
Human cell-derived microparticles promote thrombus formation in vivo in a tis-
sue factor-dependent manner. J Thromb Haemost 2003;1(12):2561–8.
[93] Shet AS, Aras O, Gupta K, Hass MJ, Rausch DJ, Saba N, et al. Sickle blood contains
tissue factor-positive microparticles derived from endothelial cells and mono-
cytes. Blood 2003;102(7):2678–83.
[94] van Beers EJ, Schaap MC, Berckmans RJ, Nieuwland R, Sturk A, van Doormaal FF,
et al. Circulating erythrocyte-derived microparticles are associated with coagu-
lation activation in sickle cell disease. Haematologica 2009;94(11):1513–9.
[95] Mallat Z, Benamer H, Hugel B, Benessiano J, Steg PG, Freyssinet JM, et al. Elevated
levels of shed membrane microparticles with procoagulant potential in the
peripheral circulating blood of patients with acute coronary syndromes. Circula-
tion 2000;101(8):841–3.
[96] Morel O, Jesel L, Freyssinet JM, Toti F. Elevated levels of procoagulant micropar-
ticles in a patient with myocardial infarction, antiphospholipid antibodies and
multifocal cardiac thrombosis. Thromb J 2005;3:15.
[97] Trappenburg MC, van SM, Marchetti M, Spronk HM, ten CH, Leyte A, et al. Elevat-
ed procoagulant microparticles expressing endothelial and platelet markers in
essential thrombocythemia. Haematologica 2009;94(7):911–8.
[98] Tesselaar ME, Romijn FP, van der Linden IK, Bertina RM, Osanto S. Microparticle-
associated tissue factor activity in cancer patients with and without thrombosis.
J Thromb Haemost 2009;7(8):1421–3.
[99] Darbousset R, Thomas GM, Mezouar S, Frere C, Bonier R, Mackman N, et al. Tissue
factor-positive neutrophils bind to injured endothelial wall and initiate thrombus
formation. Blood 2012;120(10):2133–43.
[100] Davila M, Amirkhosravi A, Coll E, Desai H, Robles L, Colon J, et al. Tissue factor-
bearing microparticles derived from tumor cells: impact on coagulation activation.
J Thromb Haemost 2008;6(9):1517–24.
[101] van den Goor J, Saxby B, Tijssen J, Wesnes K, de MB, Nieuwland R. Improvement
of cognitive test performance in patients undergoing primary CABG and other
CPB-assisted cardiac procedures. Perfusion 2008;23(5):267–73.
[102] Baj-Krzyworzeka M, Szatanek R, Weglarczyk K, Baran J, Urbanowicz B, Branski P,
et al. Tumour-derived microvesicles carry several surface determinants and
mRNA of tumour cells and transfer some of these determinants to monocytes.
Cancer Immunol Immunother 2006;55(7):808–18.
[103] Baj-Krzyworzeka M, Baran J, Weglarczyk K, Szatanek R, Szaﬂarska A, Siedlar M,
et al. Tumour-derived microvesicles (TMV) mimic the effect of tumour cells on
monocyte subpopulations. Anticancer Res 2010;30(9):3515–9.
[104] Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR. Impaired
phagocytosis of apoptotic cell material by monocyte-derived macrophages from
patientswith systemic lupus erythematosus. Arthritis Rheum1998;41(7):1241–50.
[105] Lima LG, Chammas R, Monteiro RQ, Moreira ME, Barcinski MA. Tumor-
derived microvesicles modulate the establishment of metastatic melanoma in a
phosphatidylserine-dependent manner. Cancer Lett 2009;283(2):168–75.
[106] Boing AN, Hau CM, Sturk A, Nieuwland R. Platelet microparticles contain active
caspase 3. Platelets 2008;19(2):96–103.
[107] Tait JF, Smith C. Phosphatidylserine receptors: role of CD36 in binding of anionic
phospholipid vesicles to monocytic cells. J Biol Chem 1999;274(5):3048–54.
[108] Chironi G, Simon A, Hugel B, Del PM, Gariepy J, Freyssinet JM, et al. Circulating
leukocyte-derived microparticles predict subclinical atherosclerosis burden in
asymptomatic subjects. Arterioscler Thromb Vasc Biol 2006;26(12):2775–80.
[109] Ueba T, Nomura S, Inami N, Nishikawa T, Kajiwara M, Iwata R, et al. Plasma level
of platelet-derived microparticles is associated with coronary heart disease risk
score in healthy men. J Atheroscler Thromb 2010;17(4):342–9.
[110] Nozaki T, Sugiyama S, Koga H, Sugamura K, Ohba K, Matsuzawa Y, et al. Signiﬁ-
cance of a multiple biomarkers strategy including endothelial dysfunction to im-
prove risk stratiﬁcation for cardiovascular events in patients at high risk for
coronary heart disease. J Am Coll Cardiol 2009;54(7):601–8.
[111] Janowska-Wieczorek A, Majka M, Kijowski J, Baj-Krzyworzeka M, Reca R, Turner
AR, et al. Platelet-derived microparticles bind to hematopoietic stem/progenitor
cells and enhance their engraftment. Blood 2001;98(10):3143–9.
[112] Baglio SR, Pegtel DM, Baldini N. Mesenchymal stem cell secreted vesicles provide
novel opportunities in (stem) cell-free therapy. Front Physiol 2012;3:359.
[113] Bruno S, Grange C, Deregibus MC, Calogero RA, Saviozzi S, Collino F, et al. Mesen-
chymal stem cell-derived microvesicles protect against acute tubular injury. J Am
Soc Nephrol 2009;20(5):1053–67.[114] Kim SH, Lechman ER, Bianco N, Menon R, Keravala A, Nash J, et al. Exosomes de-
rived from IL-10-treated dendritic cells can suppress inﬂammation and
collagen-induced arthritis. J Immunol 2005;174(10):6440–8.
[115] Chaput N, Flament C, Viaud S, Taieb J, Roux S, Spatz A, et al. Dendritic cell
derived-exosomes: biology and clinical implementations. J Leukoc Biol 2006;80(3):
471–8.
[116] Le Pecq JB. Dexosomes as a therapeutic cancer vaccine: from bench to bedside.
Blood Cells Mol Dis 2005;35(2):129–35.
[117] Altieri SL, Khan AN, Tomasi TB. Exosomes from plasmacytoma cells as a tumor
vaccine. J Immunother 2004;27(4):282–8.
[118] Yuana Y, Bertina RM, Osanto S. Pre-analytical and analytical issues in the analysis
of blood microparticles. Thromb Haemost 2011;105(3):396–408.
[119] Lamparski HG, Metha-Damani A, Yao JY, Patel S, Hsu DH, Ruegg C, et al. Produc-
tion and characterization of clinical grade exosomes derived from dendritic cells.
J Immunol Methods 2002;270(2):211–26.
[120] Zeelenberg IS, Ostrowski M, Krumeich S, Bobrie A, Jancic C, Boissonnas A, et al.
Targeting tumor antigens to secreted membrane vesicles in vivo induces efﬁ-
cient antitumor immune responses. Cancer Res 2008;68(4):1228–35.
[121] Van Der Pol E, van Gemert MJ, Sturk A, Nieuwland R, Van Leeuwen TG. Single vs.
swarm detection of microparticles and exosomes by ﬂow cytometry. J Thromb
Haemost 2012;10(5):919–30.
[122] Tait JF, Gibson D. Phospholipid binding of annexin V: effects of calcium and
membrane phosphatidylserine content. Arch Biochem Biophys 1992;298(1):
187–91.
[123] Shi J, Heegaard CW, Rasmussen JT, Gilbert GE. Lactadherin binds selectively to
membranes containing phosphatidyl-L-serine and increased curvature. Biochim
Biophys Acta 2004;1667(1):82–90.
[124] Nomura S, Shouzu A, Taomoto K, Togane Y, Goto S, Ozaki Y, et al. Assessment of
an ELISA kit for platelet-derived microparticles by joint research at many insti-
tutes in Japan. J Atheroscler Thromb 2009;16(6):878–87.
[125] Yuana Y, Oosterkamp TH, Bahatyrova S, Ashcroft B, Garcia RP, Bertina RM, et al.
Atomic force microscopy: a novel approach to the detection of nanosized blood
microparticles. J Thromb Haemost 2010;8(2):315–23.
[126] Siedlecki CA, Wang IW, Higashi JM, Kottke-Marchant K, Marchant RE.
Platelet-derived microparticles on synthetic surfaces observed by atomic
force microscopy and ﬂuorescence microscopy. Biomaterials 1999;20(16):
1521–9.
[127] Baran J, Baj-Krzyworzeka M, Weglarczyk K, Szatanek R, Zembala M, Barbasz J,
et al. Circulating tumour-derived microvesicles in plasma of gastric cancer pa-
tients. Cancer Immunol Immunother 2010;59(6):841–50.
[128] Gyorgy B, Modos K, Pallinger E, Paloczi K, Pasztoi M, Misjak P, et al. Detection
and isolation of cell-derived microparticles are compromised by protein com-
plexes resulting from shared biophysical parameters. Blood 2011;117(4):
e39–48.
[129] Soo CY, Song Y, Zheng Y, Campbell EC, Riches AC, Gunn-Moore F, et al. Nanopar-
ticle tracking analysis monitors microvesicle and exosome secretion from im-
mune cells. Immunology 2012;136(2):192–7.
[130] Gercel-Taylor C, Atay S, Tullis RH, Kesimer M, Taylor DD. Nanoparticle analysis of
circulating cell-derived vesicles in ovarian cancer patients. Anal Biochem
2012;428(1):44–53.
[131] Filipe V, Hawe A, Jiskoot W. Critical evaluation of Nanoparticle Tracking Analysis
(NTA) by NanoSight for the measurement of nanoparticles and protein aggre-
gates. Pharm Res 2010;27(5):796–810.
[132] Dragovic RA, Gardiner C, Brooks AS, Tannetta DS, Ferguson DJ, Hole P, et al.
Sizing and phenotyping of cellular vesicles using Nanoparticle Tracking Analysis.
Nanomedicine 2011;7(6):780–8.
[133] Redman CW, Tannetta DS, Dragovic RA, Gardiner C, Southcombe JH, Collett GP,
et al. Review: does size matter? Placental debris and the pathophysiology of
pre-eclampsia. Placenta 2012;33(Suppl.):S48–54.
[134] Sharma S, Rasool HI, Palanisamy V, Mathisen C, Schmidt M, Wong DT, et al.
Structural-mechanical characterization of nanoparticle exosomes in human saliva,
using correlative AFM, FESEM, and force spectroscopy. ACS Nano 2010;4(4):
1921–6.
[135] Ashcroft BA, de SJ, Yuana Y, Osanto S, Bertina R, Kuil ME. Determination of the
size distribution of blood microparticles directly in plasma using atomic force
microscopy and microﬂuidics. Biomed Microdevices 2012;14(4):641–9.
[136] van der Vlist EJ, Nolte-'t Hoen EN, Stoorvogel W, Arkesteijn GJ, Wauben MH.
Fluorescent labeling of nano-sized vesicles released by cells and subsequent
quantitative and qualitative analysis by high-resolution ﬂow cytometry. Nat
Protoc 2012;7(7):1311–26.
[137] Hoen EN, van der Vlist EJ, Aalberts M, Mertens HC, Bosch BJ, Bartelink W, et al.
Quantitative and qualitative ﬂow cytometric analysis of nanosized cell-derived
membrane vesicles. Nanomedicine 2012;8(5):712–20.
[138] Wolf P. The nature and signiﬁcance of platelet products in human plasma. Br
J Haematol 1967;13(3):269–88.
[139] Denzer K, van EM, Kleijmeer MJ, Jakobson E, de GC, Geuze HJ. Follicular dendritic
cells carry MHC class II-expressing microvesicles at their surface. J Immunol
2000;165(3):1259–65.
[140] Turiak L, Misjak P, Szabo TG, Aradi B, Paloczi K, Ozohanics O, et al. Proteomic
characterization of thymocyte-derived microvesicles and apoptotic bodies in
BALB/c mice. J Proteomics 2011;74(10):2025–33.
[141] Zomer A, Vendrig T, Hopmans ES, van EM, Middeldorp JM, Pegtel DM. Exosomes:
ﬁt to deliver small RNA. Commun Integr Biol 2010;3(5):447–50.
